Atossa Genetics (ATOS) PT Raised to $25 at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar raised the price target on Atossa Genetics (NASDAQ: ATOS) to $25.00 (from $7.00) while maintaining a Buy rating.
The analyst commented: "On March 25, after market close, Atossa reported 4Q25 earnings and provided a corporate update highlighting Z-endoxifen's (Z-endox) clinical and regulatory progress in breast cancer (BC) as well as its emerging potential in Duchenne muscular dystrophy (DMD). Most notably, the company secured 2 key FDA designations for (Z)-endox in DMD: (1) Rare Pediatric Disease designation and (2) Orphan Drug Designation, underscoring the FDA's recognition of the unmet need in this patient population and potentially positioning Atossa for an expedited review pathway and market exclusivity, if approved. We are modulating our price target to $25 following a 1-for-15 reverse stock split."